Northern Trust Corp Synthetic Biologics, Inc. Transaction History

Northern Trust Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.9 - $2.9 $10,653 - $16,260	-5,607 Reduced 1.67%	330,792 $70,000
Q1 2022 May 13, 2022	BUY	$2.3 - $4.3 $209,299 - $391,300	91,000 Added 37.08%	336,399 $96,000
Q2 2021 Aug 13, 2021	SELL	$4.6 - $7.2 $5,257 - $8,229	-1,143 Reduced 0.46%	245,399 $148,000
Q1 2021 May 12, 2021	BUY	$5.0 - $11.7 $1.16 Million - $2.72 Million	232,896 Added 1706.7%	246,542 $168,000
Q4 2020 Feb 11, 2021	SELL	$2.9 - $4.6 $43,096 - $68,360	-14,861 Reduced 52.13%	13,646 $5,000
Q3 2020 Nov 16, 2020	BUY	$4.5 - $7.1 $35,500 - $56,011	7,889 Added 38.26%	28,507 $14,000
Q1 2020 May 14, 2020	BUY	$2.7 - $6.1 $55,668 - $125,769	20,618 New	20,618 $7,000

Ticker SYN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,844,100
Market Cap $9.51M
Description
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.